Maternal ADHD and Perinatal Prescription Stimulant Use

Meena N. Murugappan; Sarah M. Westberg; Stephen Contag; Tanya E. Melnik; Arun Kumar; Abhijeet Rajpurohit; Katie Thorsness; Joel F Farley

doi:10.1177/10870547211073472

Maternal ADHD and Perinatal Prescription Stimulant Use

Meena N. Murugappan, Sarah M. Westberg, Stephen Contag, Tanya E. Melnik, Arun Kumar, Abhijeet Rajpurohit, Katie Thorsness, Joel F Farley

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Objective: To describe patterns and predictors of perinatal prescription stimulant use. Methods: We used MarketScan^® commercial claims data (2013–2018) and a repeated cross-sectional study design to assess perinatal use of prescription stimulants. Clinical/demographic characteristics were compared across cohorts of women who continued versus discontinued stimulant treatment at various stages of pregnancy. Associations were tested for significance using chi-square tests (categorical variables) and independent t-tests (continuous variables). Results: Out of 612,001 pregnancies, 15,413 involved pre-pregnancy stimulant use. Of these, stimulant treatment was discontinued prior to conception in 6,416 (42%), discontinued during trimester 1 in 5,977 (39%), and continued into later trimesters in 3,020 (19%). Compared with pregnancies involving stimulant discontinuation prior to conception, those that continued into pregnancy occurred in women who were older (29.9 vs. 28.9 years) and had more severe ADHD (3.1 vs. 1.8 ADHD-related billing claims). Conclusions: There is considerable heterogeneity in the management of ADHD during pregnancy.

Original language	English (US)
Pages (from-to)	1347-1356
Number of pages	10
Journal	Journal of Attention Disorders
Volume	26
Issue number	10
DOIs	https://doi.org/10.1177/10870547211073472
State	Published - Aug 2022

Bibliographical note

Funding Information:
The authors would like to acknowledge Sarah Jane Brown, MSc for her contributions to the literature review for this manuscript. The author(s) received no financial support for the research, authorship, and/or publication of this article.

Publisher Copyright:
© ©The Author(s) 2022.

Keywords

ADHD
Truven MarketScan
in utero exposure
maternal health
mental health
pregnancy
pregnancy complications
stimulants
Central Nervous System Stimulants/adverse effects
Cross-Sectional Studies
Humans
Pregnancy
Female
Attention Deficit Disorder with Hyperactivity/drug therapy
Prescriptions

PubMed: MeSH publication types

Journal Article

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1177/10870547211073472

Find It

Find It at U of M Libraries

Cite this

@article{162075f7eafa4178bd7e4a4abb6841a3,

title = "Maternal ADHD and Perinatal Prescription Stimulant Use",

abstract = "Objective: To describe patterns and predictors of perinatal prescription stimulant use. Methods: We used MarketScan{\textregistered} commercial claims data (2013–2018) and a repeated cross-sectional study design to assess perinatal use of prescription stimulants. Clinical/demographic characteristics were compared across cohorts of women who continued versus discontinued stimulant treatment at various stages of pregnancy. Associations were tested for significance using chi-square tests (categorical variables) and independent t-tests (continuous variables). Results: Out of 612,001 pregnancies, 15,413 involved pre-pregnancy stimulant use. Of these, stimulant treatment was discontinued prior to conception in 6,416 (42%), discontinued during trimester 1 in 5,977 (39%), and continued into later trimesters in 3,020 (19%). Compared with pregnancies involving stimulant discontinuation prior to conception, those that continued into pregnancy occurred in women who were older (29.9 vs. 28.9 years) and had more severe ADHD (3.1 vs. 1.8 ADHD-related billing claims). Conclusions: There is considerable heterogeneity in the management of ADHD during pregnancy.",

keywords = "ADHD, Truven MarketScan, in utero exposure, maternal health, mental health, pregnancy, pregnancy complications, stimulants, Central Nervous System Stimulants/adverse effects, Cross-Sectional Studies, Humans, Pregnancy, Female, Attention Deficit Disorder with Hyperactivity/drug therapy, Prescriptions",

author = "Murugappan, {Meena N.} and Westberg, {Sarah M.} and Stephen Contag and Melnik, {Tanya E.} and Arun Kumar and Abhijeet Rajpurohit and Katie Thorsness and Farley, {Joel F}",

note = "Funding Information: The authors would like to acknowledge Sarah Jane Brown, MSc for her contributions to the literature review for this manuscript. The author(s) received no financial support for the research, authorship, and/or publication of this article. Publisher Copyright: {\textcopyright} {\textcopyright}The Author(s) 2022.",

year = "2022",

month = aug,

doi = "10.1177/10870547211073472",

language = "English (US)",

volume = "26",

pages = "1347--1356",

journal = "Journal of Attention Disorders",

issn = "1087-0547",

publisher = "SAGE Publications Inc.",

number = "10",

}

TY - JOUR

T1 - Maternal ADHD and Perinatal Prescription Stimulant Use

AU - Murugappan, Meena N.

AU - Westberg, Sarah M.

AU - Contag, Stephen

AU - Melnik, Tanya E.

AU - Kumar, Arun

AU - Rajpurohit, Abhijeet

AU - Thorsness, Katie

AU - Farley, Joel F

N1 - Funding Information: The authors would like to acknowledge Sarah Jane Brown, MSc for her contributions to the literature review for this manuscript. The author(s) received no financial support for the research, authorship, and/or publication of this article. Publisher Copyright: © ©The Author(s) 2022.

PY - 2022/8

Y1 - 2022/8

N2 - Objective: To describe patterns and predictors of perinatal prescription stimulant use. Methods: We used MarketScan® commercial claims data (2013–2018) and a repeated cross-sectional study design to assess perinatal use of prescription stimulants. Clinical/demographic characteristics were compared across cohorts of women who continued versus discontinued stimulant treatment at various stages of pregnancy. Associations were tested for significance using chi-square tests (categorical variables) and independent t-tests (continuous variables). Results: Out of 612,001 pregnancies, 15,413 involved pre-pregnancy stimulant use. Of these, stimulant treatment was discontinued prior to conception in 6,416 (42%), discontinued during trimester 1 in 5,977 (39%), and continued into later trimesters in 3,020 (19%). Compared with pregnancies involving stimulant discontinuation prior to conception, those that continued into pregnancy occurred in women who were older (29.9 vs. 28.9 years) and had more severe ADHD (3.1 vs. 1.8 ADHD-related billing claims). Conclusions: There is considerable heterogeneity in the management of ADHD during pregnancy.

AB - Objective: To describe patterns and predictors of perinatal prescription stimulant use. Methods: We used MarketScan® commercial claims data (2013–2018) and a repeated cross-sectional study design to assess perinatal use of prescription stimulants. Clinical/demographic characteristics were compared across cohorts of women who continued versus discontinued stimulant treatment at various stages of pregnancy. Associations were tested for significance using chi-square tests (categorical variables) and independent t-tests (continuous variables). Results: Out of 612,001 pregnancies, 15,413 involved pre-pregnancy stimulant use. Of these, stimulant treatment was discontinued prior to conception in 6,416 (42%), discontinued during trimester 1 in 5,977 (39%), and continued into later trimesters in 3,020 (19%). Compared with pregnancies involving stimulant discontinuation prior to conception, those that continued into pregnancy occurred in women who were older (29.9 vs. 28.9 years) and had more severe ADHD (3.1 vs. 1.8 ADHD-related billing claims). Conclusions: There is considerable heterogeneity in the management of ADHD during pregnancy.

KW - ADHD

KW - Truven MarketScan

KW - in utero exposure

KW - maternal health

KW - mental health

KW - pregnancy

KW - pregnancy complications

KW - stimulants

KW - Central Nervous System Stimulants/adverse effects

KW - Cross-Sectional Studies

KW - Humans

KW - Pregnancy

KW - Female

KW - Attention Deficit Disorder with Hyperactivity/drug therapy

KW - Prescriptions

UR - http://www.scopus.com/inward/record.url?scp=85123256092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85123256092&partnerID=8YFLogxK

U2 - 10.1177/10870547211073472

DO - 10.1177/10870547211073472

M3 - Article

C2 - 35048729

AN - SCOPUS:85123256092

SN - 1087-0547

VL - 26

SP - 1347

EP - 1356

JO - Journal of Attention Disorders

JF - Journal of Attention Disorders

IS - 10

ER -

Maternal ADHD and Perinatal Prescription Stimulant Use

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this